Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated